(Q84315174)
Statements
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study (English)
Akihiko Asahina
Hidemi Nakagawa
Takafumi Etoh
Mamitaro Ohtsuki
Adalimumab M04-688 Study Group